Enveric Biosciences Files 8-K: Material Agreement & Equity Sales
Ticker: ENVB · Form: 8-K · Filed: Sep 18, 2025 · CIK: 890821
| Field | Detail |
|---|---|
| Company | Enveric Biosciences, Inc. (ENVB) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.01, $3.00, $0.915, $2.2 million, $35,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: ENVB
TL;DR
Enveric Bio (ENVB) filed an 8-K detailing a new material agreement and equity sales.
AI Summary
Enveric Biosciences, Inc. announced on September 17, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing details are for the period ending September 17, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Enveric Biosciences, Inc. (company) — Registrant
- September 17, 2025 (date) — Date of earliest event reported
- 245 First Street, Riverview II, 18th Floor Cambridge (location) — Business Address
FAQ
What is the nature of the material definitive agreement entered into by Enveric Biosciences?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before September 17, 2025.
What type of equity securities were sold unregistered?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
What are the key financial statements and exhibits included in this filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided header information.
When was Enveric Biosciences, Inc. incorporated?
Enveric Biosciences, Inc. was incorporated in Delaware.
What is the primary business of Enveric Biosciences, Inc. according to its SIC code?
According to its Standard Industrial Classification (SIC) code 2834, Enveric Biosciences, Inc. is involved in Pharmaceutical Preparations.
Filing Stats: 2,584 words · 10 min read · ~9 pages · Grade level 13.9 · Accepted 2025-09-18 16:30:54
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar
- $3.00 — bruary 3, 2025, at an exercise price of $3.00 per share (collectively, the "Existing
- $0.915 — Warrants at a reduced exercise price of $0.915 per share in consideration for the Comp
- $2.2 million — gregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warra
- $35,000 — and the issuance of the New Warrants of $35,000 for its non-accountable expenses, up to
- $50,000 — for its non-accountable expenses, up to $50,000 for its accountable expenses and $15,95
- $15,950 — 50,000 for its accountable expenses and $15,950 for its clearing costs. The Company has
- $1.1438 — ts will have an exercise price equal to $1.1438 per share (125% of the offering price).
Filing Documents
- form8-k.htm (8-K) — 67KB
- ex4-1.htm (EX-4.1) — 137KB
- ex4-2.htm (EX-4.2) — 130KB
- ex4-3.htm (EX-4.3) — 131KB
- ex10-1.htm (EX-10.1) — 62KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-2.htm (EX-99.2) — 15KB
- 0001493152-25-014073.txt ( ) — 837KB
- envb-20250917.xsd (EX-101.SCH) — 3KB
- envb-20250917_lab.xml (EX-101.LAB) — 33KB
- envb-20250917_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 18, 2025 ENVERIC BIOSCIENCES, INC. By: /s/ Joseph Tucker Joseph Tucker, Ph.D. Chief Executive Officer